17.26
price down icon0.40%   -0.07
after-market Handel nachbörslich: 17.32 0.06 +0.35%
loading
Schlusskurs vom Vortag:
$17.33
Offen:
$17.08
24-Stunden-Volumen:
155.76K
Relative Volume:
0.84
Marktkapitalisierung:
$1.16B
Einnahmen:
$-9,000
Nettoeinkommen (Verlust:
$-68.03M
KGV:
-16.44
EPS:
-1.05
Netto-Cashflow:
$-44.76M
1W Leistung:
-13.14%
1M Leistung:
+18.87%
6M Leistung:
+4.35%
1J Leistung:
+4.48%
1-Tages-Spanne:
Value
$16.76
$17.47
1-Wochen-Bereich:
Value
$16.76
$20.20
52-Wochen-Spanne:
Value
$13.77
$25.00

Pulse Biosciences Inc Stock (PLSE) Company Profile

Name
Firmenname
Pulse Biosciences Inc
Name
Telefon
510-906-4600
Name
Adresse
3957 POINT EDEN WAY, HAYWARD, CA
Name
Mitarbeiter
75
Name
Twitter
@PulseBioNPS
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
PLSE's Discussions on Twitter

Vergleichen Sie PLSE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Instruments & Supplies icon
PLSE
Pulse Biosciences Inc
17.26 1.18B -9,000 -68.03M -44.76M -1.05
Medical Instruments & Supplies icon
ISRG
Intuitive Surgical Inc
436.39 156.20B 9.15B 2.63B 1.99B 7.1661
Medical Instruments & Supplies icon
BDX
Becton Dickinson Co
188.36 53.50B 21.39B 1.61B 2.55B 5.5609
Medical Instruments & Supplies icon
RMD
Resmed Inc
270.07 39.84B 5.15B 1.40B 1.65B 9.5082
Medical Instruments & Supplies icon
ALC
Alcon Inc
74.08 35.89B 10.03B 1.07B 1.39B 2.1549
Medical Instruments & Supplies icon
WST
West Pharmaceutical Services Inc
261.17 18.87B 2.96B 487.70M 344.00M 6.6758

Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-07 Eingeleitet Oppenheimer Outperform
2021-07-27 Eingeleitet Stephens Overweight
2021-03-11 Eingeleitet Maxim Group Buy
2021-01-26 Bestätigt H.C. Wainwright Buy
2020-05-12 Hochstufung H.C. Wainwright Neutral → Buy
2020-02-14 Herabstufung H.C. Wainwright Buy → Neutral
2019-02-25 Eingeleitet H.C. Wainwright Buy
Alle ansehen

Pulse Biosciences Inc Aktie (PLSE) Neueste Nachrichten

pulisher
03:12 AM

Using data filters to optimize entry into Pulse Biosciences Inc.July 2025 Trade Ideas & AI Based Buy and Sell Signals - newser.com

03:12 AM
pulisher
03:00 AM

Why hedge funds are buying Pulse Biosciences Inc. stockTreasury Yields & AI Powered Market Entry Ideas - newser.com

03:00 AM
pulisher
Oct 13, 2025

Is this a good reentry point in Pulse Biosciences Inc.July 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Using fundamentals and technicals on Pulse Biosciences Inc.Portfolio Performance Report & High Return Trade Opportunity Guides - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Sector ETF performance correlation with Pulse Biosciences Inc.2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Visualizing Pulse Biosciences Inc. stock with heatmapsBear Alert & Detailed Earnings Play Strategies - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Pulse Biosciences Unveils Promising First-in-Human Data for nPulse - Yahoo Finance

Oct 13, 2025
pulisher
Oct 13, 2025

Tick level data insight on Pulse Biosciences Inc. volatility2025 Buyback Activity & Daily Growth Stock Tips - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

Will Pulse Biosciences Inc. stock beat EPS estimates2025 Major Catalysts & Technical Entry and Exit Tips - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

Pulse Biosciences (PLSE): Assessing Valuation After Recent Share Price Swings - Yahoo Finance

Oct 11, 2025
pulisher
Oct 10, 2025

Pulse Biosciences’ Npulse successful in epicardial PFA - BioWorld MedTech

Oct 10, 2025
pulisher
Oct 10, 2025

Pulse Biosciences Reveals Positive First-in-Human PFA Data - Medical Product Outsourcing

Oct 10, 2025
pulisher
Oct 10, 2025

Is Pulse Biosciences Inc. stock bottoming outJuly 2025 Institutional & Low Risk Entry Point Tips - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Pulse Biosciences announces presentation of late-breaking data from the nPulse cardiac surgical system - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

Pulse Biosciences Announces Results from nPulse Cardiac Surgical System Study - TradingView

Oct 10, 2025
pulisher
Oct 10, 2025

Pulse Biosciences reports positive results for cardiac ablation system By Investing.com - Investing.com Nigeria

Oct 10, 2025
pulisher
Oct 10, 2025

Pulse Biosciences, Inc. Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

Pulse Biosciences reports positive results for cardiac ablation system - Investing.com India

Oct 10, 2025
pulisher
Oct 10, 2025

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire

Oct 10, 2025
pulisher
Oct 10, 2025

Is now a turning point for Pulse Biosciences Inc.July 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Pulse Biosciences (NASDAQ:PLSE) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Heatmap analysis for Pulse Biosciences Inc. and competitorsJuly 2025 Trends & Long-Term Capital Growth Strategies - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Will Pulse Biosciences Inc. continue its uptrendMarket Activity Summary & Real-Time Sentiment Analysis - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

What analysts say about Pulse Biosciences Inc 6L8 stockTrendline Breakouts & Outstanding Investment Portfolio - earlytimes.in

Oct 08, 2025
pulisher
Oct 07, 2025

Insider Selling: Pulse Biosciences (NASDAQ:PLSE) Insider Sells 4,600 Shares of Stock - MarketBeat

Oct 07, 2025
pulisher
Oct 07, 2025

Pulse Biosciences introduces nPulse Vybrance for nsPFA technology - Traders Union

Oct 07, 2025
pulisher
Oct 07, 2025

Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Investing News Network

Oct 07, 2025
pulisher
Oct 07, 2025

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Business Wire

Oct 07, 2025
pulisher
Oct 03, 2025

Pulse Biosciences (NASDAQ:PLSE) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Pulse Biosciences (PLSE) Is Up 11.1% After FDA Clears Cardiac Ablation StudyWhat's Changed - Sahm

Oct 03, 2025
pulisher
Oct 03, 2025

Pulse Biosciences (PLSE): Evaluating Its Valuation After Recent Investor Interest - Sahm

Oct 03, 2025
pulisher
Oct 03, 2025

Using Ichimoku Cloud for Pulse Biosciences Inc. technicals2025 Dividend Review & Technical Buy Zone Confirmation - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

What does recent volatility data suggest for Pulse Biosciences Inc.Buy Signal & Momentum Based Trading Signals - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Pulse Biosciences Expands Equity Incentive Plan - MSN

Oct 02, 2025
pulisher
Oct 01, 2025

Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial - Insider Monkey

Oct 01, 2025
pulisher
Sep 29, 2025

What drives Pulse Biosciences Inc 6L8 stock priceStock Buy Signals & Invest Now – Opportunity Window Closing - earlytimes.in

Sep 29, 2025
pulisher
Sep 29, 2025

First Procedures Conducted in PRECISE Benign Thyroid Nodule Study - Medical Product Outsourcing

Sep 29, 2025

Finanzdaten der Pulse Biosciences Inc-Aktie (PLSE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Pulse Biosciences Inc-Aktie (PLSE) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Danahy Kevin Patrick
Chief Commercial Officer
Oct 02 '25
Sale
18.53
4,600
85,238
43,298
Danahy Kevin Patrick
Chief Commercial Officer
Sep 18 '25
Option Exercise
1.53
20,000
30,600
63,298
Danahy Kevin Patrick
Chief Commercial Officer
Sep 19 '25
Option Exercise
1.53
400
612
43,698
Danahy Kevin Patrick
Chief Commercial Officer
Sep 18 '25
Sale
18.49
20,000
369,800
43,298
Danahy Kevin Patrick
Chief Commercial Officer
Sep 19 '25
Sale
18.48
400
7,392
43,298
UECKER DARRIN
Chief Technology Officer
Sep 17 '25
Option Exercise
4.00
181,534
726,136
284,406
UECKER DARRIN
Chief Technology Officer
Sep 16 '25
Option Exercise
4.00
25,000
100,000
147,872
UECKER DARRIN
Chief Technology Officer
Sep 16 '25
Sale
16.28
25,000
407,000
122,872
UECKER DARRIN
Chief Technology Officer
Sep 17 '25
Sale
16.21
20,000
324,200
122,872
$13.91
price up icon 0.94%
medical_instruments_supplies BAX
$22.82
price up icon 3.21%
$71.49
price up icon 0.86%
medical_instruments_supplies COO
$71.21
price up icon 2.76%
$65.92
price up icon 0.63%
medical_instruments_supplies WST
$261.17
price down icon 0.50%
Kapitalisierung:     |  Volumen (24h):